Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01774578
• Other study ID #: NLG0301
• Secondary ID: 1209-1184
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: February 2013
• Est. completion date: June 18, 2016

Study information

• Verified date: May 2020
• Source: Lumos Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung immunotherapy versus Docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.

Description:

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death in men and women in the United States. Despite advances in the treatment of advanced NSCLC in the last decade, survival outcomes remain poor. Treatment benefit from cytotoxic chemotherapy has reached a plateau and further progress will depend upon identifying novel methods to target tumor cells.

Harnessing the human immune system to target lung cancer could result in the development of effective treatment options against lung cancer and potentially enhance the effect of cytotoxic chemotherapy. Lung cancer cells produce a number of abnormal proteins or abnormal amounts of certain proteins found in normal lung cells. In some cancers, the abnormal protein expression may lead to an immune response against the cancer cells much in the way the immune system responds to an infection. In progressive lung cancer however, the immune system fails to identify or respond to these abnormalities and the cancer cells are not attacked or destroyed for reasons not yet fully understood. This clinical trial proposes a novel method to stimulate the immune system to recognize the abnormal components found in lung cancer cells and to stimulate an immune response that destroys or blocks the growth of the cancer.

This new method of treatment helps the immune system of lung cancer patients to "identify" and target the cancerous tissue. As an example, patients who receive an organ transplant to replace a damaged kidney or heart are treated with special drugs to supress their immune response from destroying or "rejecting" the transplanted organ. This "rejection" occurs when the patient's immune system responds to differences between the cells of the transplanted organ and their own immune system by attacking the foreign tissue in the same way as it would attack infected tissue. When the differences between foreign tissues and the patient's body are even larger, perhaps like differences between organs from pigs and the immune system cells of humans, the rejection is very rapid, highly destructive and the immunity it generates is long-lasting. This is called hyperacute rejection and the medicine used to immunize patients in this protocol tries to harness this response to teach a patient's immune system to fight their lung cancer just as the body would learn to reject a transplanted organ from an animal.

To do this, we have placed a mouse gene into cultured human lung cancer cell lines. These cells will express a sugar that will stimulate a strong immune response in humans. These cancer cells are irradiated to prevent any growth and then injected along with chemotherapy to patients with lung cancer. The presence of the sugar will stimulate the patient's immune system to kill the injected immunotherapy cells. As part of the process of destroying the immunotherapy cells, the patient's immune system is stimulated to identify as many differences between these cancer cells and normal human cells. This extra stimulation is thought to encourage immune responses against the lung cancer in the patient based on shared abnormalities of lung cancer immunotherapy cells and the patient's lung cancer cells.

In this experimental therapy, patients are given docetaxel or injections of an immunotherapy consisting of three types of modified lung cancer cells. We propose to test these treatments in patients with lung cancer who have progressed after initial chemotherapy to demonstrate that treatment of immunotherapy results in improved tumor stabilization or response and could potentially improve the patient's overall survival.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 135
• Est. completion date: June 18, 2016
• Est. primary completion date: May 18, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological diagnosis of non-small cell lung cancer (NSCLC). Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma, and large cell anaplastic lung carcinoma histologies are eligible as are mixed histologies of NSCLC (i.e., adenosquamous). Mixed NSCLC/small cell lung carcinoma (SCLC), and variant large and small cell lung cancer are not eligible.

• Stage IIIB (AJCC Stage IIIB - Any T,N3M0 or T4N2M0) or Metastatic (AJCC Stage IV- any T, any N, M1), progressive, recurrent or refractory NSCLC. Patients may not be eligible for other curative intent treatment (e.g., surgical resection).

For the purpose of eligibility for this trial, the above-cited disease states are defined as follows:

• Progressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.

• Recurrent NSCLC: Defined as the re-appearance of measurable disease, or the appearance of new measurable disease by RECIST Criteria after prior successful treatment or complete response.

• Refractory NSCLC: Defined as achieving less than a complete response and having residual measurable disease by RECIST criteria after prior treatment with chemotherapy, targeted or small molecules, monoclonal antibodies or any combination of these.

• Eastern Cooperative Oncology Group (ECOG)Performance Status = 1.

• Serum albumin =3.0 gm/dL.

• Expected survival =4 months.

• Adequate organ function including:

1. Marrow: Hemoglobin =10.0 dm/dL, absolute granulocyte count (AGC)=1,000/mm^3, platelets =100,000/mm^3, absolute lymphocyte count =1000/mm^3.

2. Hepatic: Serum total bilirubin =1.5 x upper limit of normal (ULN) with the exception of <2.9 mg/dL for patients with Gilbert's disease, alanine aminotransferase (ALT/SGPT) and aspartate aminotransferase (AST/SGOT) =2.5 x ULN.

3. Renal: Serum creatinine (sCr) =1.5 x upper limit of normal, or creatinine clearance (Ccr) =50 mL/min.

• Measurable disease as defined by RECIST Criteria.

• Prior therapy for NSCLC that may include surgery, radiation therapy, immunotherapy and/or = 2 prior chemotherapy regimens (such as neoadjuvant/adjuvant treatment), however only 1 chemotherapy regimen in the metastatic setting is allowed.

• Treatment with a single course of gefitinib(Iressa®) or erlotinib (Tarceva®), or other small molecule or targeted therapies, or monoclonal antibody therapy (excluding docetaxel) will be considered and count as prior chemotherapy.

• Patients receiving preoperative (Neoadjuvant) and postoperative adjuvant chemotherapy (within 12 weeks of surgery) with the same agent(s) will be considered to have received a single chemotherapy regimen.

• Patients must be = 4 weeks since major surgery, chemotherapy (6-weeks if they were treated with a nitrosourea or mitomycin) or biotherapy/target therapies and = 2 weeks since radiotherapy.

• Patients must have the ability to understand the study, its risks, side effects, potential benefits and be able to give written informed consent to participate. Patients may not be consented by a durable power of attorney (DPA).

• Male and female subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental drug and for one month after the last immunization.

Exclusion Criteria:

• Age < 18-years-old.

• Active central nervous system (CNS) disease, metastases or carcinomatous meningitis. Patients with CNS metastases must be at least 2 weeks status post prior therapy to the brain and be off all steroids without progressing CNS disease.

• Hypercalcemia >2.9 mmol/L, unresponsive to standard therapy (e.g., I.V. hydration, diuretics, calcitonin and/or bisphosphate therapy).

• Pregnant or nursing women due to the unknown effects of immunization on the developing fetus or newborn infant.

• Other malignancy within three years, unless the probability of recurrence is <5%. Patients curatively treated for squamous cell carcinoma and basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix (CIN) or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.

• History of organ transplant, or current active immunosuppressive therapy (such as cyclosporine, tacrolimus, etc.).

• Subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible. Decadron treatment with docetaxel is acceptable.

• Significant or uncontrolled congestive heart failure (CHF), myocardial infarction, significant ventricular arrhythmias within the last six months or significant pulmonary dysfunction.

• Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever (temp > 38.1°C) if deemed clinically significant by the treating physician.

• Autoimmune disease (e.g., systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), etc.). Patients with a remote history of asthma or mild active asthma are eligible.

• Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., liver cirrhosis).

• Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).

• A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.

• Patients having undergone splenectomy.

• Known HIV positive.

• Subjects who received any prior treatment with docetaxel are excluded. Subjects who have received gemcitabine in first line therapy but do not have squamous cell carcinoma, will be eligible as they can receive pemetrexed for the salvage regimen.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer Recurrent
• Progression of Non-small Cell Lung Cancer

Intervention

Drug:
• Docetaxel
Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.

Biological:
• HyperAcute®-Lung Immunotherapy
HAL-1, HAL-2 and HAL-3 immunotherapy components. Up to 16 immunizations of 300 million immunotherapy cells.

Drug:
• Gemcitabine
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
• Pemetrexed
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.

Locations

Country	Name	City	State
United States	Illinois Cancer Specialists	Arlington Heights	Illinois
United States	Gabrail Cancer Center	Canton	Ohio
United States	Northwestern University	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	University of Cincinnati	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Deaconess Clinic	Evansville	Indiana
United States	University of Kansas Cancer Center	Fairway	Kansas
United States	University of Florida	Gainesville	Florida
United States	Indiana University Health Goshen Center for Cancer Care	Goshen	Indiana
United States	Vince Lombardi Cancer Clinic	Green Bay	Wisconsin
United States	Indiana University	Indianapolis	Indiana
United States	Kansas City VA Medical Center	Kansas City	Missouri
United States	University of Tennessee Medical Center	Knoxville	Tennessee
United States	Lynchburg Hematology Oncology Clinic	Lynchburg	Virginia
United States	University of Wisconsin	Madison	Wisconsin
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	St. Joseph Heritage Healthcare	Santa Rosa	California
United States	Stamford Hospital	Stamford	Connecticut
United States	Richmond University Medical Center	Staten Island	New York
United States	North Mississippi Hematology and Oncology Associates at BridgePoint	Tupelo	Mississippi
United States	Wake Forest Baptist Health	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
NewLink Genetics Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The primary objective in Phase IIB and Phase III is to assess overall survival of anti-tumor immunization using HyperAcute®-Lung (HAL) Immunotherapy versus docetaxel in patients with progressed or relapsed non-small cell lung cancer (NSCLC) that have been previously treated.	Approximately 19 months, assuming a 24 month enrollment.
Secondary	Dosing schedule	A secondary objective in Phase IIB is to determine the response rates of HyperAcute®-Lung (HAL) Immunotherapy given in a weekly and biweekly regimen versus docetaxel.	Approximately 19 months, assuming a 24 month enrollment.
Secondary	Tumor response rate	A secondary outcome measure in Phase IIB and Phase III is to measure tumor response including response to follow-on salvage regimens to assess chemosensitization effects.	Approximately 19 months, assuming a 24 month enrollment.
Secondary	Immunologic Response	A secondary outcome measure in Phase IIB and Phase III is to assess the immunological response of patients with lung cancer treated with HyperAcute®-Lung (HAL) Immunotherapy versus docetaxel in patients with progressed or relapsed NSCLC that have been previously treated.	Approximately 19 months, assuming a 24 month enrollment.

External Links

•   Click here for more information regarding NewLink Genetics.